Myezom 2 mg Injection
  1. Home
  2. Pharma Products
  3. Dr Reddy 's Laboratories Ltd
  4. Myezom 2 mg Injection

Myezom 2 mg Injection

Myezom 2 mg Injection contains bortezomib 2 mg, a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. It is administered by a qualified healthcare professional according to the prescribed treatment schedule. Bortezomib interferes with proteasome activity, causing abnormal proteins to accumulate in cancer cells and promoting their death.

BUY NOW

Category

Myezom 2 mg Injection is used as part of specific treatment regimens for multiple myeloma and mantle cell lymphoma. Bortezomib blocks proteasomes, cellular structures responsible for breaking down proteins, which disrupts the function and survival of malignant cells. The medicine may be administered by intravenous or subcutaneous injection depending on the prescribed regimen and clinical protocol. Dose, treatment schedule, and duration are determined by the treating oncologist with appropriate clinical and laboratory monitoring.

Technical Specification

Specification Details
Active Ingredient Bortezomib
Strength 2 mg
Dosage Form Powder for Injection
Route Intravenous / Subcutaneous
Pack Size 1 Vial
Manufacturer/Marketer Dr. Reddy’s Laboratories Ltd.

Product Also Known As

Myezom 2 mg Injection, Myezom 2 Injection, Myezom Bortezomib Injection, Bortezomib 2 mg Injection, Bortezomib Multiple Myeloma Injection, Bortezomib Proteasome Inhibitor Injection